May 20, 2024

Biopsy Needle Market Size to Reach USD 2.60 Billion by 2033

The global biopsy needle market size reached USD 1.30 billion in 2023 and is projected to attain around USD 2.60 billion by 2033, growing at a CAGR of 7.17% from 2024 to 2033.

Key Points

  • The North America biopsy needle market size surpassed USD 520 million in 2023 and is predicted to hit around USD 1,030 million by 2033.
  • North America dominated the global biopsy needle market with the largest market share of 39.7% in 2023.
  • Asia Pacific is considered to register the fastest growth with a significant CAGR during the forecast period.
  • By-product, the biopsy needle guns segment has held the largest share of 62% in 2023.
  • By application, the cancer segment has accounted largest market share of 46% in 2023.
  • By end-user, the hospitals segment has registered the largest market share of 58% in 2023.

Biopsy Needle Market Size 2024 to 2033

The biopsy needle market is a vital segment within the broader medical device industry, playing a crucial role in the diagnosis and treatment of various medical conditions, including cancer. Biopsy needles are specialized medical instruments used to extract tissue samples from the body for laboratory analysis. These samples are essential for accurate diagnosis, prognosis, and treatment planning in oncology, infectious diseases, inflammatory conditions, and other medical specialties.

The global biopsy needle market has experienced significant growth in recent years, driven by factors such as increasing incidences of cancer and other chronic diseases, advancements in biopsy techniques and technologies, growing demand for minimally invasive procedures, and expanding healthcare infrastructure worldwide. As healthcare systems focus more on early detection and personalized medicine, the demand for biopsy needles is expected to continue rising, presenting opportunities for market players to innovate and expand their product offerings.

Get a Sample:

Growth Factors:

Several key factors are driving the growth of the biopsy needle market. One of the primary drivers is the rising incidence of cancer globally. As the prevalence of cancer increases due to factors such as aging populations, lifestyle changes, and environmental factors, the need for accurate and timely diagnosis becomes paramount. Biopsy needles play a crucial role in obtaining tissue samples for histopathological examination, aiding in the early detection and treatment of cancer.

Furthermore, advancements in biopsy needle technologies have led to the development of more precise, efficient, and minimally invasive biopsy procedures. Innovations such as vacuum-assisted biopsy (VAB) systems, core biopsy needles, and ultrasound-guided biopsy devices have improved the accuracy of tissue sampling while reducing patient discomfort and procedural complications. These technological advancements have expanded the application of biopsy needles beyond oncology to areas such as infectious diseases, autoimmune disorders, and genetic testing.

Moreover, the growing adoption of image-guided biopsy techniques, such as ultrasound, MRI, and CT scans, has increased the demand for biopsy needles compatible with these imaging modalities. These techniques enable physicians to target specific lesions or abnormalities with greater precision, enhancing the diagnostic yield of biopsy procedures. As healthcare providers strive to offer more comprehensive and accurate diagnostic services, the demand for advanced biopsy needle systems is expected to rise significantly.

Region Insights:

The biopsy needle market exhibits regional variations influenced by factors such as healthcare infrastructure, regulatory environment, reimbursement policies, and disease epidemiology. North America accounts for a significant share of the global market, driven by the presence of well-established healthcare systems, high healthcare expenditure, and a large patient population with chronic diseases, including cancer. The region is also characterized by extensive research and development activities, fostering technological innovation and product advancements in biopsy needle technology.

Europe is another prominent market for biopsy needles, supported by favorable government initiatives, robust healthcare infrastructure, and increasing investments in cancer screening and early detection programs. Countries such as Germany, France, and the United Kingdom are key contributors to the European market, owing to their advanced healthcare systems and high incidence of cancer.

In the Asia Pacific region, the biopsy needle market is witnessing rapid growth due to factors such as rising healthcare expenditure, improving access to healthcare services, and increasing awareness about cancer screening and early detection. Countries such as China, India, and Japan are experiencing a surge in demand for biopsy needles, driven by expanding population demographics, growing prevalence of cancer, and initiatives to improve healthcare infrastructure.

Biopsy Needle Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 7.17%
Global Market Size in 2023 USD 1.30 Billion
Global Market Size in 2024 USD 1.39 Billion
Global Market Size by 2033 USD 2.60 Billion
Largest Market North America
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Product, By Application, and By End-use
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Biopsy Needle Market Dynamics


Several drivers are propelling the growth of the biopsy needle market. Firstly, the increasing prevalence of cancer globally is a major driver, necessitating efficient and accurate diagnostic tools for early detection and treatment planning. Biopsy needles play a crucial role in obtaining tissue samples for histopathological examination, enabling clinicians to make informed decisions regarding patient management.

Secondly, technological advancements in biopsy needle design and functionality are driving market growth. Innovations such as vacuum-assisted biopsy systems, core biopsy needles, and ultrasound-guided biopsy devices have improved the accuracy, safety, and efficiency of biopsy procedures, leading to better patient outcomes and reduced procedural complications.

Additionally, the growing adoption of minimally invasive biopsy techniques is fueling market growth. Minimally invasive procedures offer several advantages over traditional open surgeries, including reduced patient discomfort, shorter recovery times, and lower healthcare costs. Biopsy needles are integral to minimally invasive biopsy techniques such as percutaneous needle biopsy, endoscopic biopsy, and image-guided biopsy, driving demand for these devices.

Moreover, increasing healthcare expenditure and investments in healthcare infrastructure are driving market growth. As healthcare systems strive to improve patient outcomes and reduce the burden of chronic diseases such as cancer, there is a growing emphasis on early detection, diagnosis, and treatment. This has led to increased adoption of biopsy needles and other diagnostic tools, driving market expansion.


Despite the promising growth prospects, the biopsy needle market faces several challenges that may impede its growth trajectory. One of the primary challenges is the lack of awareness and accessibility to biopsy services, particularly in low- and middle-income countries. Limited access to healthcare facilities, inadequate infrastructure, and socioeconomic barriers hinder the timely diagnosis and treatment of cancer and other diseases, limiting the demand for biopsy needles in these regions.

Furthermore, reimbursement issues pose a significant challenge to market growth. Reimbursement policies vary widely across different healthcare systems and payers, affecting the affordability and accessibility of biopsy procedures for patients. In some cases, reimbursement may not cover the full cost of biopsy procedures or may require prior authorization, leading to financial barriers for patients and healthcare providers.

Moreover, safety concerns and procedural complications associated with biopsy procedures pose challenges to market growth. While biopsy needles are generally considered safe and minimally invasive, they carry risks such as bleeding, infection, tissue damage, and pneumothorax, especially in complex biopsy procedures or in patients with underlying health conditions. Addressing these safety concerns and improving procedural outcomes through technological advancements and training programs is essential to overcome this challenge.


Despite the challenges, the biopsy needle market presents several opportunities for growth and innovation. One of the key opportunities lies in expanding market penetration in emerging economies with growing healthcare infrastructure and rising disease burden. By investing in market development initiatives, expanding distribution networks, and partnering with local healthcare providers, companies can tap into new growth markets and address unmet medical needs.

Furthermore, there is a growing trend towards personalized medicine and targeted therapy in oncology, driven by advances in genomics, molecular diagnostics, and immunotherapy. Biopsy needles play a critical role in obtaining tissue samples for genetic testing, biomarker analysis, and molecular profiling, enabling clinicians to tailor treatment strategies to individual patients. Capitalizing on this trend by developing specialized biopsy needle systems for molecular diagnostics and precision medicine presents lucrative opportunities for market players.

Moreover, ongoing research and development efforts aimed at improving biopsy needle design, functionality, and performance offer opportunities for product innovation and differentiation. By investing in R&D initiatives, collaborating with academic institutions and research organizations, and leveraging emerging technologies such as artificial intelligence and robotics, companies can develop next-generation biopsy needle systems with enhanced capabilities and improved patient outcomes.

Read Also: Agricultural Biologicals Market Size to Reach USD 39.59 Bn by 2033

Recent Developments

  • In 2022, Cambridge Enterprise introduced their biopsy device named ‘CamPROBE’. The prostate biopsy device aims to reduce the risks related to conventional transrectal biopsies.
  • In 2022, Mammatome introduced their dual-core biopsy system which marked their first step in the core biopsy market. The device reduces the vibrations and needle movements and helps to enhance the patient experience.
  • In 2022, Limaca Medical received its breakthrough device through the FDA for its Precision-GI endoscopic ultrasound biopsy needle. The invention aims to reduce issues like blood contamination, tissue fragmentation, and less collection of sample quantity during the entire procedure.
  • In 2021, Hologic Inc. acquired a company named Somatex Technologies for 64 million, aiming to increase the treatment offerings for breast cancer.

Biopsy Needle Market Companies

  • Becton
  • Medtronic Plc
  • Cardinal Health
  • Hologic Inc
  • Olympus Corporation
  • Argon Medical Devices Inc
  • Devicor Medical Products, Inc
  • B. Braun Melsungen AG
  • Cook Group Incorporated
  • Boston Scientific Corporation
  • FUJIFILM Holdings Corporation
  • Dickinson and Company
  • Stryker Corporation
  • INRAD, Inc

Segments Covered in the Report

By Product

  • Biopsy Needle Guns
    • Vacuum-assisted Biopsy Devices
    • Fine Needle Aspiration Biopsy
    • Core Needle Biopsy Devices
  • Biopsy Needles
    • Disposable
    • Reusable

By Application

  • Cancer
    • Breast
    • Lung
    • Prostate
    • Colon
    • Stomach
    • Liver
    • Other cancer
  • Autoimmune Disorder
  • Infectious Diseases
  • Others

By End-use

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333






Leave a Reply

Your email address will not be published. Required fields are marked *